SEK 7.74
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Data is available to registered users only